Loading
Angela DeMichele led the first palbociclib clinical trial and co-leads the I-SPY 2 adaptive platform.
Angela DeMichele is Co-Leader of the Breast Cancer Research Program and the Alan and Jill Miller Professor in Breast Cancer Excellence at the Abramson Cancer Center, University of Pennsylvania. She is a medical oncologist known for conducting the first palbociclib clinical trial in breast cancer and for co-leading the I-SPY 2 adaptive platform trial. Her selected paper reports the phase 2 activity, safety and predictive biomarkers of the CDK4/6 inhibitor palbociclib in Rb-positive advanced breast cancer. She now studies disseminated tumour cell dormancy as a target for preventing late recurrence in hormone receptor-positive and triple-negative breast cancer.
| Title | Journal | Year |
|---|---|---|
| CDK 4/6 inhibitor palbociclib (PD0332991) in Rb+ advanced breast cancer: phase II activity, safety, and predictive biomarker assessment | Clinical Cancer Research | 2015 |
Shares CDK4/6, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares CDK4/6, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares CDK4/6, Palbociclib, HR-positive / HER2-negative breast cancer.
Shares CDK4/6, Palbociclib, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares Abramson Cancer Center, University of Pennsylvania, Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer.
Shares CDK4/6, Palbociclib, HR-positive / HER2-negative breast cancer.
Shares Palbociclib, HR-positive / HER2-negative breast cancer.
Shares CDK4/6, Palbociclib, HR-positive / HER2-negative breast cancer.